Cargando…

A study of the efficacy and tolerability of capecitabine and lobaplatin in advanced HER-2 negative breast cancer patients

BACKGROUND: This study sought to examine the efficacy and adverse reactions of capecitabine and lobaplatin in the treatment of metastatic human epidermal growth factor receptor 2 (HER-2) negative breast cancer (BC). METHODS: This retrospective study examined 45 patients diagnosed with advanced HER-2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Yuan, Zhang, Lili, Zhang, Zhe, Qian, Yu, Teng, Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350665/ https://www.ncbi.nlm.nih.gov/pubmed/34430592 http://dx.doi.org/10.21037/atm-21-2702

Ejemplares similares

Retrospective study of the efficacy and toxicity of lobaplatin in combined chemotherapy for metastatic breast cancer
por: Wu, Yuan, et al.
Publicado: (2019)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles
por: Zhong, Yuxin, et al.
Publicado: (2020)

The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer
por: Zhou, Ning-ning, et al.
Publicado: (2018)

A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
por: Yan, Min, et al.
Publicado: (2022)

Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis
por: Hu, Yiyi, et al.
Publicado: (2023)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2010)

A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
por: Wu, Xiujuan, et al.
Publicado: (2018)

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018)

Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
por: Gamucci, T., et al.
Publicado: (2013)

UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
por: Hua, Jun, et al.
Publicado: (2021)

Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial
por: Ke, Liang-Ru, et al.
Publicado: (2017)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
por: Chilà, Giovanna, et al.
Publicado: (2021)

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients
por: Xu, Bing-He, et al.
Publicado: (2011)

Lobaplatin: Multiple toxicities: case report.
Publicado: (2020)

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
por: Cao, Jun, et al.
Publicado: (2023)

Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer
por: Gu, Liyan, et al.
Publicado: (2019)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis
por: Xun, Xueqiong, et al.
Publicado: (2022)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer
por: Li, Fenghu, et al.
Publicado: (2019)

Efficacy of transcatheter arterial chemoembolization using pirarubicin-loaded microspheres combined with lobaplatin for primary liver cancer
por: Zhang, Chao, et al.
Publicado: (2022)

Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
por: Wang, Zhipeng, et al.
Publicado: (2018)

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer
por: Lee, Jieun, et al.
Publicado: (2017)

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
por: He, Maiyue, et al.
Publicado: (2023)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
por: Kaufman, Bella, et al.
Publicado: (2008)

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells
por: Wu, Qiong, et al.
Publicado: (2010)

Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease
por: Kawakami, Hisato, et al.
Publicado: (2022)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo
por: Zhou, Zijun, et al.
Publicado: (2020)

The anti-tumor effects of the combination of microwave hyperthermia and lobaplatin against breast cancer cells in vitro and in vivo
por: Li, Xiaohu, et al.
Publicado: (2022)

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
por: Baselga, J, et al.
Publicado: (2011)

Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Alvarado-Miranda, Alberto, et al.
Publicado: (2023)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
por: Hsu, C-H, et al.
Publicado: (2010)

Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study
por: Lu, Haohao, et al.
Publicado: (2023)

Lobaplatin-Based Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastasis from Appendiceal and Colorectal Cancer: Safety and Efficacy Profiles
por: Pei, Wei, et al.
Publicado: (2020)

Lobaplatin inhibits breast cancer progression, cell proliferation while it induces cell apoptosis by downregulating MTDH expression
por: Tian, Wuguo, et al.
Publicado: (2018)

A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer
por: Lu, Zhihao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_i5fcdlhnk7v4jdgrtjasn8bg02